Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Dec;38(6):527–532. doi: 10.1111/j.1365-2125.1994.tb04394.x

A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects.

A Grove 1, C Allam 1, L C McFarlane 1, G McPhate 1, C M Jackson 1, B J Lipworth 1
PMCID: PMC1364916  PMID: 7888291

Abstract

1. The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices. 2. A randomised, single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler (B800) for 1 week, followed by 1 week of 1600 micrograms day-1 (B1600), or fluticasone Diskhaler 750 micrograms day-1 (F750) for 1 week followed by 1 week of 1500 micrograms day-1 (F1500). There was a 1 week washout between treatments with fluticasone or budesonide. A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects. 3. Parameters of hypothalmic-pituitary adrenal (HPA) axis activity and bone metabolism were measured at baseline (B0/F0), at the end of each week of treatment and after the 1 week washout (F0 or B0). 4. Both fluticasone and budesonide significantly (P < 0.05) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged. No dose-response effect was observed with either drug, and there was no significant difference between treatment with fluticasone or budesonide. 5. Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin, although the higher doses of both drugs significantly reduced fasting urinary calcium levels.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
527

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ali N. J., Capewell S., Ward M. J. Bone turnover during high dose inhaled corticosteroid treatment. Thorax. 1991 Mar;46(3):160–164. doi: 10.1136/thx.46.3.160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bain B. M., Harrison G., Jenkins K. D., Pateman A. J., Shenoy E. V. A sensitive radioimmunoassay, incorporating solid-phase extraction, for fluticasone 17-propionate in plasma. J Pharm Biomed Anal. 1993 Jul;11(7):557–561. doi: 10.1016/0731-7085(93)80005-l. [DOI] [PubMed] [Google Scholar]
  3. Barnes N. C., Marone G., Di Maria G. U., Visser S., Utama I., Payne S. L. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J. 1993 Jun;6(6):877–885. [PubMed] [Google Scholar]
  4. Borgström L., Bondesson E., Morén F., Trofast E., Newman S. P. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994 Jan;7(1):69–73. doi: 10.1183/09031936.94.07010069. [DOI] [PubMed] [Google Scholar]
  5. Brown P. H., Blundell G., Greening A. P., Crompton G. K. Screening for hypothalamo-pituitary-adrenal axis suppression in asthmatics taking high dose inhaled corticosteroids. Respir Med. 1991 Nov;85(6):511–516. doi: 10.1016/s0954-6111(06)80269-6. [DOI] [PubMed] [Google Scholar]
  6. Fabbri L., Burge P. S., Croonenborgh L., Warlies F., Weeke B., Ciaccia A., Parker C. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax. 1993 Aug;48(8):817–823. doi: 10.1136/thx.48.8.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Harding S. M. The human pharmacology of fluticasone propionate. Respir Med. 1990 Nov;84 (Suppl A):25–29. doi: 10.1016/s0954-6111(08)80004-2. [DOI] [PubMed] [Google Scholar]
  8. Jennings B. H., Andersson K. E., Johansson S. A. Assessment of systemic effects of inhaled glucocorticosteroids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol. 1991;40(1):77–82. doi: 10.1007/BF00315143. [DOI] [PubMed] [Google Scholar]
  9. Johansson S. A., Andersson K. E., Brattsand R., Gruvstad E., Hedner P. Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. Eur J Clin Pharmacol. 1982;22(6):523–529. doi: 10.1007/BF00609625. [DOI] [PubMed] [Google Scholar]
  10. Lipworth B. J. Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacol Ther. 1993;58(2):173–209. doi: 10.1016/0163-7258(93)90049-j. [DOI] [PubMed] [Google Scholar]
  11. Melchor R., Biddiscombe M. F., Mak V. H., Short M. D., Spiro S. G. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax. 1993 May;48(5):506–511. doi: 10.1136/thx.48.5.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pedersen S., Steffensen G., Ohlsson S. V. The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler. Br J Clin Pharmacol. 1993 Sep;36(3):211–214. doi: 10.1111/j.1365-2125.1993.tb04219.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ryrfeldt A., Andersson P., Edsbäcker S., Tönnesson M., Davies D., Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl. 1982;122:86–95. [PubMed] [Google Scholar]
  14. Selroos O., Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax. 1991 Dec;46(12):891–894. doi: 10.1136/thx.46.12.891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Toogood J. H., Crilly R. G., Jones G., Nadeau J., Wells G. A. Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis. Am Rev Respir Dis. 1988 Jul;138(1):57–61. doi: 10.1164/ajrccm/138.1.57. [DOI] [PubMed] [Google Scholar]
  16. Toogood J. H., Jennings B., Hodsman A. B., Baskerville J., Fraher L. J. Effects of dose and dosing schedule of inhaled budesonide on bone turnover. J Allergy Clin Immunol. 1991 Oct;88(4):572–580. doi: 10.1016/0091-6749(91)90150-m. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES